| Poster Code | Presenter | Institution | Title | |
|---|---|---|---|---|
| P01 | Elena Cubero | Gain Therapeutics Sucursal en España, Barcelona, Spain | Screening for novel inhibitors of Mycobacterium tuberculosis dihydrofolate reductase using structure-based virtual screening | P01 Elena Cubero |
| P02 | Elena Anaya-Cubero | Clinical Neuroproteomics Laboratory, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IDISNA, Pamplona, Navarra, Spain. | TRANSLATING OMICS-DRIVEN DRUG REPURPOSING INTO EXPERIMENTAL MODELS OF ALZHEIMER’S DISEASE | P02 Elena Anaya-Cubero |
| P03 | Rinaldo Wander Montalvão | Gain Therapeutics Sucursal en España | Transforming Drug Discovery: Generative Models and Electrostatic Complementarity | P03 Rinaldo Wander Montalvão |
| P04 | Marina De Miguel | Clinical Neuroproteomics Unit, Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. | Rucaparib as a repurposed therapeutic strategy for Parkinson’s Disease: in vitro and in vivo validation. | P04 Marina De Miguel |
| P05 | Irena Montiel | Promega Biotech Iberica, Madrid, España | Quantitative Live-Cell Analysis Of GPCR Signaling Dynamics Using Endogenous Bioluminescent Reporters: From Ligand Engagement To Downstream Effector Activation | P05 Irena Montiel |
| P06 | Silvia Romero-Murillo | Clinical Neuroproteomics Unit, Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Navarra Institute for Health Research (IdiSNA), Pamplona, Spain | Uncovering Novel Therapeutic Candidates for Alzheimer’s Disease Through Integrative Omics-Based Drug Repurposing | P06 Silvia Romero-Murillo |
| P07 | Manuel Novás | Universidad de Santiago de Compostela | From our lab to a European library: bioprofiling our compounds through EU-OPENSCREEN | P07 Manuel Novás |
| P08 | Marta Martínez-García | Fundación Medina | PROSPLIGN project: Prospecting Natural Lignin for Antitumor Activity: Unlocking the Potential of a Sustainable Biopolymer | P08 Marta Martínez-García |
| P09 | Santiago Vázquez | Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona | EDDU: Early Drug Discovery Unit | P09 Santiago Vázquez |
| P10 | Jairo Paz | GalChimia | Development of novel drug candidates for selective inhibition of Bcl-2 protein-protein interactions | P10 Jairo Paz |
| P11 | María Jurado-Pueyo | Promega | BRETSA: An ultra-sensitive, broadly-applicable BRET method to measure target engagement and cooperativity in cells using protein denaturation | P11 María Jurado-Pueyo |
| P12 | Stefano Benvegnù | Aptadel Therapeutics, Parc Cientific de Barcelona, 08028 Barcelona, Spain | Precision aptamers for aggressive cancer | P12 Stefano Benvegnù |
| P13 | Nuria valls | ALBA Synchrotron | ALBA SYNCHROTRON: A CUTTING-EDGE RESOURCE FOR PHARMACEUTICAL COMPANIES | P13 Nuria valls |
| P14 | Carmen Ramos | Fundacion MEDINA | Synergizing Multicellular Spheroids/Organoids, Microbial Natural Products, High Content Screening, and AI for Triple Negative Breast Cancer Therapy Discovery | P14 Carmen Ramos |
| P15 | Adrian Velazquez-Campoy | University of Zaragoza, Institute BIFI | Leveraging conformational heterogeneity in proteins for drug discovery | P15 Adrian Velazquez-Campoy |
| P16 | Cristina Val | BioFarma research group | Development of a UHPLC-MS/MS Method for the Simultaneous Quantification of 18 Steroids to Expand the H295R Steroidogenesis Assay | P16 Cristina Val |
| P17 | Alberto Pitarch Sanz | Centro de Investigación Príncipe Felipe (CIPF) - Polymer Therapeutics Lab | AlphaScreen-Enabled Small Extracellular Vesicle Analysis Supports Hepatocellular Carcinoma Biomarker Detection, Patient Stratification, and Drug Discovery | P17 Alberto Pitarch Sanz |
| P18 | Esther Masia | Polymer Therapeutics Laboratory (1) and Screening Platform (2), Príncipe Felipe Research Center (CIPF). 3. Centro de Investigación Biomédica en Red Cáncer (CIBERONC). Joint unit in Advanced Therapies in Oncology CIPF-Universitat Jaume I (UJI) (5) | HIGH-THROUGHPUT 3D PHENOTYPIC SCREENING REVEALS NOVEL THERAPEUTIC OPPORTUNITIES IN PERITONEAL CARCINOMATOSIS | P18 Esther Masia |
| P19 | Carme Serra | SIMChem, Synthesis of High added Value Molecules Service, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain | SIMChem: An Integrated Platform for Synthetic, Analytical, Photochemical and Biological Services Supporting Research and Innovation | P19 Carme Serra |
| P20 | Anna Llebaria-Fabrias | MCS, Laboratory of Medicinal Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain | Photopharmacology for high precision drugs | P20 Anna Llebaria-Fabrias |
| P21 | Yoonseok Kam | Agilent Technologies | Metabolic Profiling of Tumor Organoids and Evaluation of Mitochondria-Targeting Anticancer Agents Using the Mito Tox Index | P21 Yoonseok Kam |
| P22 | Elisa Marín-Jerez | VivoArchitect Ibérica, VivoXpand, Tecnoincubadora Marie Curie, C/Leonardo da Vinci, 18, 41092 Sevilla, Spain | Ph.D. Programme in Endocrinology, University of Santiago de Compostela (USC), Santiago de Compostela, Spain | VivoArchitect, Route de la Corniche 5A, 1066 Epalinges, Switzerland. | A Short-Term Multi-Parametric Assay in Mice to Detect Early Phenotypic Changes of Longevity Interventions | P22 Elisa Marín-Jerez |
| P23 | Elisa Marín-Jerez | VivoArchitect Ibérica, VivoXpand, Tecnoincubadora Marie Curie, C/Leonardo da Vinci, 18, 41092 Sevilla, Spain | Ph.D. Programme in Endocrinology, University of Santiago de Compostela (USC), Santiago de Compostela, Spain | VivoArchitect, Route de la Corniche 5A, 1066 Epalinges, Switzerland. | Preventing Hypothermia Through Oral Supplementation in Mice | P23 Elisa Marín-Jerez |
| P24 | Luz Romero | Kærtor Foundation | Annotated Sigma Receptor Ligand Library for Drug Discovery | P24 Luz Romero |
| P25 | Carmen Monreal | Telum Therapeutics | Rewriting the Lysin Playbook: APEX®-engineered EPLETTX4 vs. Staphylococcus | P25 Carmen Monreal |
| P26 | Megan Luedeman | Promega Corporation, Madison (WI), USA | Innovative Bioluminescence Assays for Monitoring GPCR Dynamics: Advancing Therapeutic Strategies for Metabolic Disease | P26 Megan Luedeman |
| P27 | Ainoa Fayos | Centro de Investigación Príncipe Felipe | MBoIN179 targets the MCL1–BOK axis and reveals a potential therapeutic vulnerability in NSCLC | P27 Ainoa Fayos |
| P28 | Geert Daudey | Innopharma Drug Screening and Pharmacogenomics Platform | From Concept to Application: High-Throughput Solubility and Aggregation Profiling in Drug Discovery with the ORYL F1 Platform. | P28 Geert Daudey |
| P29 | Iñigo Azagra-Barber | Center for Applied Medical Research (CIMA), University of Navarra (UNAV) | Expanding the E3 ligase toolbox towards tumour-selective targeted protein degradation using DNA Encoded Libraries. | P29 Iñigo Azagra-Barber |
| P30 | Juan Manuel Prieto | LUCAI BIO / Department of Biological Chemistry, University of Buenos Aires, IQUIBICEN-CONICET | From Pocket to ΔG: an open, end-to-end physics pipeline for structure-based hit-to-lead discovery | P30 Juan Manuel Prieto |
| P31 | Antonio Gómez | Kaertor Foundation, Santiago de Compostela, Spain | The Spanish Chemical Compound Library: A Resource to Support Biomedical Research | P31 Antonio Gómez |
¿Quieres saber más sobre nuestros socios protectores y patrocinadores?